Technical Articles

CD22 is a member of the sialic acid-binding immunoglobulin-type lectin family, a type I transmembrane protein that specifically binds to sialic acid-containing glycans and inhibits B-cell receptor signaling through its immunoreceptor tyrosine-based inhibitory motif, thereby maintaining humoral immune homeostasis.

The KRAS gene, a member of the RAS family with the highest mutation frequency, plays a critical driving role in the occurrence and development of various malignant tumors.

Acute myeloid leukemia is a highly heterogeneous group of hematologic malignancies, and its prognosis assessment involves multiple factors. Traditionally, age, history of hematologic disorders, karyotype, and gene mutation profiles have been important bases for evaluating patient prognosis, and these factors collectively determine the selection of treatment strategies.

The KRAS gene is one of the most frequently mutated oncogenes in human malignancies, with approximately 30% of high-mortality tumors associated with KRAS mutations.

Colorectal cancer is one of the most prevalent malignant tumors in China. With the advancement of precision medicine, its treatment strategies increasingly rely on in-depth analysis of the tumor's molecular characteristics.

Pancreatic cancer, due to its hidden anatomical location, atypical early symptoms, rapid progression, and limited treatment options, has long ranked among the top in malignancy mortality rates, earning it the title "king of cancers."

Colorectal cancer is the second most common malignant tumor globally and the fourth leading cause of cancer-related deaths.

Bladder cancer is a common malignant tumor of the urinary system, and its clinical treatment faces core challenges such as high recurrence rates, significant pathological heterogeneity, and limited treatment options.

The advent of tumor immunotherapy, particularly immune checkpoint blockade therapy, has significantly transformed the treatment landscape for various malignant tumors.

In the complex landscape of lymph system malignancies, identifying highly specific tumor-associated antigens is crucial for developing effective immunotherapies.